EpiVax Demonstrates Antigen-Specific Tolerance Induction in Allergy with Tregitopes, Results Published in Frontiers in Immunology
Frontiers
in Immunology. This research highlights Tregitopes as a promising therapy for allergy. Administration of IgG-derived Tregitopes were found to induce suppressive antigen-specific T-regulatory cells in ovalbumin (OVA) and ragweed-allergic murine mouse models, attenuating allergen-induced airway hyperresponsiveness and lung inflammation.
Tregitopes are peptides found in human immunoglobulin which were first discovered in 2008 by Dr. Anne De Groot and William Martin. EpiVax has since validated many more Tregitopes and has developed a strong Tregitope patent estate. With a wide range of therapeutic applications, Tregitopes can be co-formulated or fused to proteins to induce antigen-specific tolerance. EpiVax is currently licensing Tregitope with commercial and academic partners. More information on the EpiVax Tregitope Platform is available here.
The Quebec Health Ministry has confirmed the death of a woman in the province after the AstraZeneca-Oxford COVID-19 vaccine she received in early April led to a rare blood clot in her brain.
War among COVID-19 variants playing out in Quebec By the end of this month, the more transmissible new variants will account for 91 per cent of all COVID-19 transmissions here.
Author of the article: René Bruemmer
Publishing date: Apr 23, 2021 • 5 hours ago • 5 minute read • People line up at a COVID-19 vaccination centre in Deux-Montagnes on Friday. It s a race against time. We have to vaccinate the most people possible so they can t transmit the disease, said Michel Roger, medical director of Quebec’s public health laboratory. Photo by Ryan Remiorz /The Canadian Press
Article content
In Quebec, biological warfare is being waged among a handful of COVID-19 variants in an ongoing battle for supremacy.
What level of vaccination will it take for tide to turn? Experts weigh in Younger people are happily showing up in droves for the AstraZeneca shot, not as fearful about the low risk of blood clots as their elders.
Author of the article: Michelle Lalonde • Montreal Gazette
Publishing date: Apr 23, 2021 • 1 minute ago • 5 minute read • More people in the 45 to 54 age group (329,316 people) got the AstraZeneca shot or made an appointment to do so on the first day they were eligible than did those in the 55 to 59 age group in the over two weeks they have been eligible. Photo by Paul Chiasson /The Canadian Press
Why some experts say Quebec s plan to give different vaccine as 2nd dose is safe and necessary cbc.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cbc.ca Daily Mail and Mail on Sunday newspapers.